Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 04-Feb-14 11:09 AM View:  | McEwan Alastair Stuart CFO and Treasurer | Critical Therapeutics Inc. (CRTX) | 03-Feb-14 | Disposition | 316,413 | $9.50 | $3,005,920.00 | (100%) 316.41K to 0 | (< 1%) |
| 04-Feb-14 10:58 AM View: | Collard Craig A Chief Executive Officer Director | Critical Therapeutics Inc. (CRTX) | 03-Feb-14 | Disposition | 45,000 | $9.50 | $427,500.00 | (100%) 45.0K to 0 | (< 1%) |
| 04-Feb-14 11:08 AM View: | McBean Kenneth President | Critical Therapeutics Inc. (CRTX) | 03-Feb-14 | Disposition | 83,705 | $9.50 | $795,198.00 | (100%) 83.7K to 0 | (< 1%) |
| 04-Feb-14 11:10 AM View: | Roberts Alan VP, Scientific Affairs | Critical Therapeutics Inc. (CRTX) | 03-Feb-14 | Disposition | 80,947 | $9.50 | $768,996.00 | (100%) 80.95K to 0 | (< 1%) |
| 04-Feb-14 10:58 AM View: | Collard Craig A Chief Executive Officer Director | Critical Therapeutics Inc. (CRTX) | 03-Feb-14 | Disposition | 1,567,220 | $9.50 | $14,888,600.00 | (97%) 1.61M to 45.0K | (< 1%) |
| 04-Feb-14 11:07 AM View: | Maetzel Andreas VP, Clinical and Regulatory | Critical Therapeutics Inc. (CRTX) | 03-Feb-14 | Disposition | 25,000 | $9.50 | $237,500.00 | (100%) 25.0K to 0 | (< 1%) |
| 04-Feb-14 10:59 AM View: | Duarte Ira Principal Accounting Officer | Critical Therapeutics Inc. (CRTX) | 03-Feb-14 | Disposition | 7,000 | $9.50 | $66,500.00 | (100%) 7.0K to 0 | (< 1%) |
| 04-Feb-14 11:05 AM View: | Franklin Joshua B VP, Strategy & Bus. Dev. | Critical Therapeutics Inc. (CRTX) | 03-Feb-14 | Disposition | 45,944 | $9.50 | $436,468.00 | (100%) 45.94K to 0 | (< 1%) |
| 17-Sep-13 4:13 PM View: | McEwan Alastair Stuart CFO and Treasurer | Critical Therapeutics Inc. (CRTX) | 15-Sep-13 | Grant | 19,172 | -- | -- | 6% 297.24K to 316.41K | |
| 30-Aug-13 5:39 PM View: | Powell Andrew Kenneth William EVP, General Counsel | Critical Therapeutics Inc. (CRTX) | 30-Aug-13 | Disposition | 27,645 | -- | -- | (24%) 117.43K to 89.78K | |
| 07-May-13 4:51 PM View: | Maetzel Andreas VP, Clinical and Regulatory | Critical Therapeutics Inc. (CRTX) | 06-May-13 | Grant | 25,000 | -- | -- | 100% 0 to 25.0K | |
| 11-Mar-13 4:36 PM View: | Duarte Ira Principal Accounting Officer | Critical Therapeutics Inc. (CRTX) | 07-Mar-13 | Grant | 7,000 | -- | -- | 100% 0 to 7.0K | |
| 07-Mar-13 4:15 PM View: | Roberts Alan VP, Scientific Affairs | Critical Therapeutics Inc. (CRTX) | 05-Mar-13 | Grant | 18,375 | -- | -- | 29% 62.57K to 80.95K | |
| 07-Mar-13 4:12 PM View: | Collard Craig A Chief Executive Officer Director | Critical Therapeutics Inc. (CRTX) | 05-Mar-13 | Grant | 45,000 | -- | -- | 3% 1.57M to 1.61M | |
| 07-Mar-13 4:17 PM View: | Franklin Joshua B VP, Strategy & Bus. Dev. | Critical Therapeutics Inc. (CRTX) | 05-Mar-13 | Grant | 25,000 | -- | -- | 119% 20.94K to 45.94K | |
| 07-Mar-13 4:18 PM View: | Powell Andrew Kenneth William EVP, General Counsel | Critical Therapeutics Inc. (CRTX) | 05-Mar-13 | Grant | 21,375 | -- | -- | 22% 96.06K to 117.43K | |
| 07-Mar-13 4:13 PM View: | McBean Kenneth President | Critical Therapeutics Inc. (CRTX) | 05-Mar-13 | Grant | 40,000 | -- | -- | 92% 43.7K to 83.7K | |
| 22-Jan-13 4:06 PM View: | McBean Kenneth President | Critical Therapeutics Inc. (CRTX) | 17-Jan-13 | Payment of Exercise | 1,217 | $5.58 | $6,790.86 | (3%) 44.92K to 43.7K | 0% |
| 08-Nov-12 4:35 PM View: | McEwan Alastair Stuart CFO and Treasurer | Critical Therapeutics Inc. (CRTX) | 06-Nov-12 | Grant | 50,000 | -- | -- | 20% 247.24K to 297.24K | |
| 06-Nov-12 4:36 PM View: | McBean Kenneth President | Critical Therapeutics Inc. (CRTX) | 05-Nov-12 | Payment of Exercise | 1,022 | $4.85 | $4,956.70 | (2%) 45.94K to 44.92K | (< 1%) |
| 12-Sep-12 4:12 PM View: | Powell Andrew Kenneth William EVP, General Counsel | Critical Therapeutics Inc. (CRTX) | 10-Sep-12 | Payment of Exercise | 2,045 | $6.27 | $12,822.20 | (2%) 98.1K to 96.06K | 1% |
| 07-Sep-12 3:25 PM View: | McBean Kenneth President | Critical Therapeutics Inc. (CRTX) | 06-Sep-12 | Payment of Exercise | 4,056 | $6.30 | $25,552.80 | (8%) 50.0K to 45.94K | < 1% |
| 30-Aug-12 3:01 PM View: | Franklin Joshua B VP, Strategy & Bus. Dev. | Critical Therapeutics Inc. (CRTX) | 29-Aug-12 | Market Option Sale | 38,637 | $6.86 | $265,050.00 | (65%) 59.58K to 20.94K | < 1% |
| 30-Aug-12 3:01 PM View: | Franklin Joshua B VP, Strategy & Bus. Dev. | Critical Therapeutics Inc. (CRTX) | 29-Aug-12 | Option Exercise | 38,637 | $3.90 | $150,684.00 | 184% 20.94K to 59.58K | |
| 28-Aug-12 4:53 PM View: | Franklin Joshua B VP, Strategy & Bus. Dev. | Critical Therapeutics Inc. (CRTX) | 24-Aug-12 | Market Option Sale | 24,688 | $7.01 | $173,063.00 | (54%) 45.63K to 20.94K | (< 1%) |
| 28-Aug-12 4:53 PM View: | Franklin Joshua B VP, Strategy & Bus. Dev. | Critical Therapeutics Inc. (CRTX) | 24-Aug-12 | Option Exercise | 24,688 | $3.90 | $96,283.20 | 118% 20.94K to 45.63K | |
| 24-Aug-12 3:14 PM View: | Morgus Vincent T. EVP, Finance and CFO | Critical Therapeutics Inc. (CRTX) | 22-Aug-12 | Payment of Exercise | 847 | $7.22 | $6,115.34 | (2%) 50.49K to 49.64K | 2% |
| 20-Jun-12 4:05 PM View: | Morgus Vincent T. EVP, Finance and CFO | Critical Therapeutics Inc. (CRTX) | 19-Jun-12 | Payment of Exercise | 787 | $5.94 | $4,674.78 | (2%) 51.28K to 50.49K | 0% |
| 08-Aug-12 5:26 PM View: | Franklin Joshua B VP, Strategy & Bus. Dev. | Critical Therapeutics Inc. (CRTX) | 28-May-12 | Payment of Exercise | 4,056 | $5.04 | $20,442.20 | (16%) 25.0K to 20.94K | (32%) |
| 30-May-12 10:19 AM View: | Roberts Alan VP, Scientific Affairs | Critical Therapeutics Inc. (CRTX) | 25-May-12 | Payment of Exercise | 5,678 | $5.04 | $28,617.10 | (8%) 68.25K to 62.57K | (3%) |
| 05-Apr-12 10:49 AM View: | Chiesi Farmaceutici Spa 10% Owner | Critical Therapeutics Inc. (CRTX) | 03-Apr-12 | Market Purchase | 1,443,910 | $6.25 | $9,024,460.00 | 10% 14.24M to 15.69M | (5%) |
| 03-Apr-12 4:14 PM View: | Collard Craig A Chief Executive Officer Director 10% Owner | Critical Therapeutics Inc. (CRTX) | 03-Apr-12 | Market Sale | 1,443,910 | $6.25 | $9,024,460.00 | (48%) 3.01M to 1.57M | 2% |
| 16-Mar-12 12:31 PM View: | Chiesi Farmaceutici Spa 10% Owner | Critical Therapeutics Inc. (CRTX) | 15-Mar-12 | Market Purchase | 3,400 | $6.08 | $20,672.00 | < 1% 14.23M to 14.24M | (1%) |
| 16-Mar-12 12:31 PM View: | Chiesi Farmaceutici Spa 10% Owner | Critical Therapeutics Inc. (CRTX) | 14-Mar-12 | Market Purchase | 3,400 | $5.99 | $20,366.00 | < 1% 14.24M to 14.24M | < 1% |
| 14-Mar-12 10:02 AM View: | Chiesi Farmaceutici Spa 10% Owner | Critical Therapeutics Inc. (CRTX) | 12-Mar-12 | Market Purchase | 3,400 | $5.85 | $19,885.20 | < 1% 14.23M to 14.24M | 6% |
| 02-Feb-12 5:26 PM View: | Morgus Vincent T. EVP, Finance and CFO | Critical Therapeutics Inc. (CRTX) | 01-Feb-12 | Payment of Exercise | 3,722 | $6.48 | $24,118.60 | (7%) 55.0K to 51.28K | 0% |
| 16-Dec-11 1:25 PM View: | Chiesi Farmaceutici Spa 10% Owner | Critical Therapeutics Inc. (CRTX) | 14-Dec-11 | Grant | 2,100 | $5.12 | $10,749.70 | < 1% 14.23M to 14.23M | 11% |
| 01-Dec-11 3:38 PM View: | Chiesi Farmaceutici Spa 10% Owner | Critical Therapeutics Inc. (CRTX) | 29-Nov-11 | Grant | 8,900 | $5.06 | $45,077.60 | < 1% 14.22M to 14.23M | 15% |
| 07-Sep-11 4:10 PM View: | McBean Kenneth President | Critical Therapeutics Inc. (CRTX) | 06-Sep-11 | Grant | 50,000 | -- | -- | 100% 0 to 50.0K | |
| 18-Jul-11 4:52 PM View: | Powell Andrew Kenneth William EVP, General Counsel | Critical Therapeutics Inc. (CRTX) | 15-Jul-11 | Market Sale | 2,000 | $8.63 | $17,260.00 | (2%) 100.1K to 98.1K | < 1% |
| 31-May-11 1:17 PM View: | Roberts Alan VP, Scientific Affairs | Critical Therapeutics Inc. (CRTX) | 26-May-11 | Market Sale | 5,850 | $7.60 | $44,460.00 | (8%) 74.1K to 68.25K | (5%) |
| 06-Apr-11 8:49 AM View: | Powell Andrew Kenneth William EVP, General Counsel | Critical Therapeutics Inc. (CRTX) | 04-Apr-11 | Market Sale (Planned) | 2,000 | $6.53 | $13,060.00 | (2%) 102.1K to 100.1K | |
| 03-Feb-11 5:22 PM View: | Morgus Vincent T. EVP, Finance and CFO | Critical Therapeutics Inc. (CRTX) | 01-Feb-11 | Grant | 55,000 | -- | -- | 100% 0 to 55.0K | |
| 10-Jan-11 4:23 PM View: | Powell Andrew Kenneth William EVP, General Counsel | Critical Therapeutics Inc. (CRTX) | 07-Jan-11 | Market Sale (Planned) | 2,000 | $5.73 | $11,460.00 | (2%) 104.1K to 102.1K | 0% |
| 20-Dec-10 6:32 PM View: | Collard Craig A President and CEO Director 10% Owner | Critical Therapeutics Inc. (CRTX) | 16-Dec-10 | Market Sale | 385,000 | $6.02 | $2,317,700.00 | (11%) 3.4M to 3.01M | 2% |
| 20-Dec-10 6:33 PM View: | Lutz Steven Michael Executive Vice President | Critical Therapeutics Inc. (CRTX) | 16-Dec-10 | Market Sale | 65,000 | $6.02 | $391,300.00 | (20%) 327.35K to 262.35K | 2% |
| 20-Dec-10 5:14 PM View: | Chiesi Farmaceutici Spa 10% Owner | Critical Therapeutics Inc. (CRTX) | 16-Dec-10 | Grant | 450,000 | $6.02 | $2,709,000.00 | 3% 13.77M to 14.22M | (2%) |
| 02-Nov-10 5:19 PM View: | Powell Andrew Kenneth William EVP, General Counsel | Critical Therapeutics Inc. (CRTX) | 01-Nov-10 | Market Sale (Planned) | 7,900 | $6.28 | $49,612.00 | (7%) 112.0K to 104.1K | 2% |
| 03-Jun-10 7:08 AM View: | Franklin Joshua B VP, Sales and Marketing | Critical Therapeutics Inc. (CRTX) | 01-Jun-10 | Market Sale | 4,129 | $5.47 | $22,585.60 | (8%) 50.0K to 45.87K | (< 1%) |
| 03-Nov-09 4:34 PM View: | Powell Andrew Kenneth William EVP, General Counsel | Critical Therapeutics Inc. (CRTX) | 30-Oct-09 | Grant | 110,000 | -- | -- | 5500% 2.0K to 112.0K |
